highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
Published 9 months ago • 1.5K plays • Length 4:17Download video MP4
Download video MP3
Similar videos
-
2:04
mariposa-2: amivantamab chemo (± lazertinib) vs chemo in egfr-mutated nsclc post-osimertinib
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
3:21
post-progression analysis of mariposa-2: amivantamab chemo in egfr nsclc
-
5:18
expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
-
0:55
mariposa update - amivantamab lazertinib in 1l egfr mutated metastatic nsclc.
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
9:02
amivantamab plus lazertinib for egfr-mutant lung cancer following progression on osimertinib
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
0:59
managing amivantamab infusion reaction #2023 #oncology #lungcancer
-
1:27
papillon phase iii primary results: amivantamab chemo vs chemo in egfr exon 20 nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
3:27
paloma-3: subcutaneous vs intravenous amivantamab lazertinib in refractory egfr-mutated nsclc
-
0:40
highlights in lung cancer at esmo 2023: papillon and mariposa
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
0:47
the future of amivantamab and lazertinib in egfr-mutant nsclc
-
1:34
pros in papillon trial: amivantamab chemo for egfr exon 20 nsclc
-
4:27
amivantamab shows robust efficacy in post-platinum therapy patients with egfr ex20ins nsclc